ANDA 76009, held by Chartwell Molecules. Nabumetone.
As of Nov 15, 2026, ANDA 76009 (Nabumetone), held by Chartwell Molecules, was first approved by FDA on Jan 24, 2003, with 5 approved supplements and 0 published complete response letters.
| Date | Submission | Status | Documents |
|---|---|---|---|
| Jan 24, 2003 | Original application | Approved | None posted |
| Nabumetone500MG · tablet;oral | Nabumetone | Rx |
| Nabumetone750MG · tablet;oral | Nabumetone | Rx |
| Nov 21, 2024 | Supplement 15Labeling · Standard review | Approved | None posted |
| May 24, 2021 | Supplement 14Labeling · Standard review | Approved | None posted |
| May 9, 2016 | Supplement 13Labeling · Standard review | Approved | None posted |
| Apr 25, 2006 | Supplement 8Labeling | Approved | None posted |
| Mar 2, 2006 | Supplement 7Labeling | Approved | None posted |
| Jan 24, 2003 | Original application | Approved | None posted |
Approvals, supplements, products and documents come from FDA's Drugs@FDA data files, refreshed daily; Drugs@FDA lists approved applications only. Complete response letters are FDA's published letters. Drugs@FDA and FDA complete response letters